These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27547884)

  • 21. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
    Mancuso ME; Mannucci PM
    Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
    Raso S; Hermans C
    Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.
    Castaman G; Linari S
    Expert Rev Hematol; 2018 Jul; 11(7):567-576. PubMed ID: 29886751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment on demand--in vivo dose finding studies.
    Escobar MA
    Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 35. Simoctocog alfa for the treatment of hemophilia A.
    Morfini M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
    Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
    Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transition considerations for extended half-life factor products.
    Croteau SE; Neufeld EJ
    Haemophilia; 2015 May; 21(3):285-288. PubMed ID: 25855484
    [No Abstract]   [Full Text] [Related]  

  • 39. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.